RecruitingNCT06751537
Effectiveness of the WearME System for COPD Severity and Respiratory Function
Effectiveness of WearME System for FEV1/FVC, Respiration and Activity Biomarkers in COPD Patients
Sponsor
LASARRUS Clinic and Research Center
Enrollment
128 participants
Start Date
May 29, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
This observational study evaluates the effectiveness of the WearME system in monitoring COPD severity and respiratory function by comparing its measurements to standard spirometry, capnography, and other clinical assessments in 128 COPD participants.
Eligibility
Min Age: 21 YearsMax Age: 100 Years
Inclusion Criteria10
- Adult participants aged 21-100 years, of any sex, and of any race/ethnicity, who are able to understand and sign consent documents in English or Spanish.
- Diagnosed with COPD as per the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria \[5\] , with the following severity levels (confirmed via spirometry performed after consent):
- Mild: FEV1/FVC \< 0.7 and FEV1 ≥ 80%
- Moderate: FEV1/FVC \< 0.7 and 50% ≤ FEV1 \< 80%
- Severe: FEV1/FVC \< 0.7 and 30% ≤ FEV1 \< 50%
- Very Severe: FEV1/FVC \< 0.7 and FEV1 \< 30% or FEV1 \< 50%, plus chronic respiratory failure.
- Note: Participants will be consented and enrolled based on prior diagnosis of COPD from medical records within the past year to confirm eligibility and stratify COPD severity levels. Spirometry will be performed during concurrent data collection with the WearME device for comparison. Screening failures are expected and will be recorded and managed appropriately.
- Current, former, or never smoker; any amount of time between quitting and study enrollment is allowed).
- Ability to understand and willingness to sign consent documents.
- Able to participate in study procedures as required.
Exclusion Criteria2
- Participants with known skin allergies or conditions that may interfere with device application or signal transmission.
- Currently receiving invasive mechanical ventilation.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06751537
Related Trials
IMPACT COPD Cohort (China)
NCT073829864 locations
Comparing Hydrocortisone and Prednisolone for Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)
NCT0689221014 locations
Long-term Real-world Study of Dupilumab in COPD : Patient Characteristics, Safety and Patient-reported Outcomes
NCT0738071120 locations
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
NCT07082738363 locations
Study of Patient With Frequent Exacerbations in Moscow
NCT073077811 location